<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739165</url>
  </required_header>
  <id_info>
    <org_study_id>ART-123-AEIPF-301</org_study_id>
    <nct_id>NCT02739165</nct_id>
  </id_info>
  <brief_title>Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>Phase III Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Multicenter Randomized Placebo-controlled Double-blind Study to Assess the Efficacy and Safety of ART-123</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asahi Kasei Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asahi Kasei Pharma Corporation</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of the intravenous drip
      infusion of ART-123 in patients with acute exacerbation of idiopathic pulmonary fibrosis
      (IPF) in a multicenter, double-blind, randomized, placebo-controlled, parallel group
      comparison study, and to confirm its superiority over placebo with survival rate on Day 90 as
      the primary endpoint.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate on Day 90</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>180 days after the start of investigational product administration in the last subject</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival time up to Day 90</measure>
    <time_frame>90days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P/F ratio</measure>
    <time_frame>4 days, 7 days, 15 days, 28 days, 60 days, 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation tests</measure>
    <time_frame>4 days, 7 days, 15days, 28 days, 60 days, 90 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Chest imaging findings (chest HRCT findings)</measure>
    <time_frame>Within 90days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood gas test</measure>
    <time_frame>Within 90days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>mMRC</measure>
    <time_frame>Within 90days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CAT</measure>
    <time_frame>Within 90days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dyspnea-12</measure>
    <time_frame>Within 90days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of respiration management</measure>
    <time_frame>Within 90days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>Within 90days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Interstitial pneumonia markers</measure>
    <time_frame>Within 90days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total duration of respiratory system-related inpatient hospitalization</measure>
    <time_frame>Within 90days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Within 90days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>AEs related to hemorrhage</measure>
    <time_frame>Within 90days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Routine laboratory tests</measure>
    <time_frame>Within 90days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Vital signs</measure>
    <time_frame>Within 90days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence of anti-drug antibodies</measure>
    <time_frame>Within 90days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>ART-123</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART-123</intervention_name>
    <description>380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy</description>
    <arm_group_label>ART-123</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo by intravenous drip infusion in addition to standard of care steroid therapy</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Patients diagnosed with IPF who meet all criteria from (1) through (4) during the
             course of IPF

          -  (1)Unexplained development or worsening of dyspnea within 1 month during the course of
             IPF

          -  (2)Finding of new, bilateral ground glass opacities and/or consolidation on HRCT

          -  (3)No apparent Pulmonary infections, pneumothorax, malignant tumors, pulmonary
             embolism, or left heart failure

          -  (4)A decrease* in PaO2 of ≥10 mmHg or SpO2 of ≥4% under the same conditions compared
             with the level at the previous measurements

               -  (*) In cases where no PaO2 or SpO2 test values under the same conditions are
                  available, a patient with a P/F ratio ≤300 in the current episode of acute
                  exacerbation is considered to have met criterion (4)

          -  Aged 40 years or older and no older than 85 years at the time of informed consent with
             either sex

        Main Exclusion Criteria:

          -  Have intracranial hemorrhage, pulmonary hemorrhage, gastrointestinal bleeding
             (continued hematemesis, bloody discharge, gastrointestinal ulcer-induced hemorrhage)

          -  Have a history of cerebrovascular disorder (e.g., cerebral hemorrhage or cerebral
             infarction) within 52 weeks (364 days) before informed consent

          -  Patients for whom the completion of hemostatic treatment has not been confirmed after
             undergoing surgery of the central nervous system or after trauma

          -  Have a high risk for fatal or life-threatening hemorrhage

          -  Patients with malignant tumors

          -  Have acute exacerbation attributable to drug induced pulmonary disorder, after surgery
             for malignant tumors, chemotherapy, or radiation therapy

          -  Have acute exacerbation due to a thoracic surgical procedure (including thoracoscopic
             lung biopsy)

          -  Have a history of acute exacerbation of IPF

          -  Receiving mechanical ventilation through intratracheal intubation

          -  Patients who are pregnant or nursing, or who may be pregnant

          -  Patients with a platelet count less than 100,000/uL at the time of enrollment

          -  Patients with severe renal (serum Cr: ≥4 mg/dL) or hepatic (AST/ALT: ≥500 IU/L or
             T-Bil: ≥10 mg/dL) dysfunction

          -  Have been administered a commercially available thrombomodulin alfa (recombinant
             )(Recomodulin® for Intravenous Injection 12800) within 30 days before the start of
             investigational product administration

          -  Have a history of hypersensitivity for investigational product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asahi Kasei Pharma Corporation</last_name>
    <role>Study Chair</role>
    <affiliation>Asahi Kasei Pharma Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asahi Kasei Pharma Corporation</last_name>
    <email>ct-info@om.asahi-kasei.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seto</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kamogawa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sakura</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ogaki</city>
        <state>Gifu</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Himeji</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Naka</city>
        <state>Ibaragi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tenri</city>
        <state>Nara</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurashiki</city>
        <state>Okanaya</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Minato</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ota</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibuya</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sinjyuku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute exacerbations</keyword>
  <keyword>Idiopathic pulmonary fibrosis</keyword>
  <keyword>Recombinant human soluble thrombomodulin</keyword>
  <keyword>ART-123</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

